来源:[1] Avidity Biosciences:《强力买入》基于Del-Zota (RNA) 加速审批申请 (https://seekingalpha.com/article/4822205-avid ...)[2] Avidity Biosciences: 基于Del-Zota加速审批申请维持“强力买入”评级 - Seeking Alpha (https://seekingalpha.com/article/4636000-avid ...)[3] KalVista Pharmaceuticals 提供运营更新并报告财季财务业绩 (https://vertexaisearch.cloud.google.com/groun ...)